PyInvesting

Market research

4KB.F 4KB

F EUR Healthcare

Latest close

285.70 —

As of Nov 19, 2026

Test a moving-average rule with historical data.

Market facts

Market cap
8B
P/E ratio
42.88
Analyst target
98.43
Dividend yield
Not available
Beta
0.65

Community

Investor discussion

1 comment

Admin profile picture
Admin

Apr 1, 2021

Krystal Biotech, Inc is currently in a long term uptrend where the price is trading 5.4% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Krystal Biotech, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 196.0% to $-16M since the same quarter in the previous year.

Finally, its free cash flow fell by 56.8% to $-12M since the same quarter in the previous year.

Based on the above factors, Krystal Biotech, Inc gets an overall score of 2/5.